BRIEF-Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission
Insight Molecular Diagnostics Inc. +20.33%
Insight Molecular Diagnostics Inc. IMDX | 3.61 | +20.33% |
March 3 (Reuters) - Insight Molecular Diagnostics Inc IMDX.O:
INSIGHT MOLECULAR DIAGNOSTICS COMPLETES KEY MILESTONES ADVANCING GRAFTASSUREDX TOWARD FDA SUBMISSION
Source text: ID:nGNX2NRcnn
Further company coverage: IMDX.O
